Study doses and treatment duration

A reference to the TRIUMPH-1 research schedule. This describes supervised study treatment; it does not select a dose or provide a self-treatment prescription.

Once-weekly dose assigned by trial stage

Study weeks	4 mg target arm	9 mg target arm	12 mg target arm
1-4	2 mg	2 mg	2 mg
5-8	4 mg	4 mg	4 mg
9-12	4 mg	6 mg	6 mg
13-16	4 mg	9 mg	9 mg
17 onward	4 mg	9 mg	12 mg

Week ranges are derived from the sponsor-described four-week escalation steps. Each arm stopped increasing at its assigned target. The target amount was not the starting amount. [1]

How long was treatment studied?

The main phase 2 obesity study evaluated 48 weeks, and the main TRIUMPH-1 phase 3 study evaluated 80 weeks. These are ongoing-treatment studies, rather than a validated short on/off cycle. [1,2]

Keep three quantities separate

Trial amount: milligrams assigned once weekly.
Container amount: total milligrams in a vial or pen.
Concentration: milligrams per millilitre of liquid.
A container label does not identify an individual treatment regimen.

Primary sources

[1] Lilly, TRIUMPH-1 protocol and efficacy results, 21 May 2026. Open original study announcement.

[2] Jastreboff et al., NEJM 2023. DOI: 10.1056/NEJMoa2301972. Open the phase 2 publication.

Concentration and sample-volume charts

Concentration = total peptide (mg) / final solution volume (mL).
Peptide in a sample = concentration (mg/mL) x sample volume (mL).

10 mg and 30 mg final-volume scenarios

Total peptide	Final volume	Concentration	Amount in 0.1 mL
10 mg	1 mL	10 mg/mL	1 mg
10 mg	2 mL	5 mg/mL	0.5 mg
10 mg	3 mL	3.333 mg/mL	0.3333 mg
30 mg	1 mL	30 mg/mL	3 mg
30 mg	2 mL	15 mg/mL	1.5 mg
30 mg	3 mL	10 mg/mL	1 mg

These are arithmetic scenarios assuming complete dissolution and the stated final volume. They do not establish solvent suitability, solubility, stability, sterility or an injection volume. The 0.1 mL column is a laboratory sample example.

Preloaded pen: 15 mg in 3 mL

15 mg / 3 mL = 5 mg/mL. A 0.1 mL laboratory aliquot at that concentration contains 0.5 mg. The pen is already a liquid; do not treat it as a powder-reconstitution example. No amount per dial unit or click is implied.

Before using a preparation chart

Check the material and lot, its documented solvent and handling requirements, the final solution volume and the calibration of the measuring equipment. Follow the laboratory SOP and product documents. Container size alone does not validate a preparation method.

Documents and live calculator

The website includes the original 10 mg and 30 mg vial reports, product documentation and a browser-local concentration calculator. HPLC area purity is not a milligram-content or sterility result.

glp-3-peptide.com/dosage/#calculator
Product specifications: 10 mg and 30 mg powder vials; 15 mg / 3 mL preloaded pen.